Biological Factors
Strategic Roadmap for Biologics Manufacturing: Enhancing Efficiency and Flexibility
Biologics manufacturing, Strategic roadmap, Process characterization, Flexibility and efficiency, Regulatory compliance, Biomanufacturing technology roadmap, Precision medicines, Modular facilities, Continuous manufacturing
Biocon Biologics Secures FDA Approval for YESINTEK, a Biosimilar to Stelara
Biocon Biologics, FDA approval, YESINTEK, Stelara biosimilar, ustekinumab, inflammatory diseases
Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Private Equity Deal
Avid Bioservices, GHO Capital Partners, Ampersand Capital Partners, biologics CDMO, private equity acquisition, $1.1 billion deal
AbbVie and EvolveImmune Therapeutics Collaborate on Next-Generation Cancer Biotherapeutics Using T-Cell Engager Technology
AbbVie, EvolveImmune Therapeutics, T-Cell Engager Technology, Next-Generation Cancer Biotherapeutics, Oncology Collaboration, Multispecific Biologics, Cancer Cell Resistance, Immunotherapies
Ocuphire Pharma Acquires Opus Genetics, Expanding into Inherited Retinal Disease Gene Therapies
Ocuphire Pharma, Opus Genetics, gene therapy, inherited retinal diseases (IRDs), merger, acquisition, biopharmaceutical, ophthalmic treatments
Samsung Biologics Secures $1.2 Billion Production Contract, Boosting 2024 Deal Value to Over $3.3 Billion
Samsung Biologics, CDMO, Contract Manufacturing, Biopharmaceuticals, Production Contract, 2024 Deal Value
WuXi AppTec and WuXi Biologics Consider Asset Sales Amid BIOSECURE Act Scrutiny
WuXi AppTec, WuXi Biologics, BIOSECURE Act, asset sales, biotech industry, US-China relations
Inventiva Secures Up to €348 Million in Financing to Advance Lanifibranor for MASH Treatment
Inventiva, Lanifibranor, MASH (Metabolic Dysfunction-Associated Steatohepatitis), Phase 3 NATiV3 Clinical Trial, Financing, Biopharmaceutical
Turnstone Biologics Undergoes Strategic Restructuring with Layoffs and Leadership Changes
Turnstone Biologics, layoffs, leadership changes, strategic restructuring, biotech industry
Resolution Therapeutics Secures £63.5M in Series B Funding to Advance Macrophage Cell Therapy for Liver Disease
Resolution Therapeutics, Series B funding, macrophage cell therapy, liver disease, regenerative medicine, biopharmaceuticals